Jul 18, 2017 8:05 am EDT Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
Jun 29, 2017 8:15 am EDT Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
Jun 2, 2017 8:05 am EDT Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
May 30, 2017 8:05 am EDT Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 25, 2017 8:05 am EDT Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 16, 2017 8:05 am EDT Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
May 12, 2017 8:05 am EDT Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
May 9, 2017 8:05 am EDT Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
May 8, 2017 8:05 am EDT Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
